STOCK TITAN

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Tempest Therapeutics (TPST), a clinical-stage biotech company focused on developing targeted cancer therapeutics, has announced a new employee compensation grant. The company's Compensation Committee approved nonqualified stock options for one employee to purchase 45,000 shares of common stock under its 2023 Inducement Plan. The options will vest over four years, with 25% vesting after the first year and the remaining portion vesting at 1/48th monthly thereafter, contingent on continued employment.

Tempest Therapeutics (TPST), un'azienda biotech in fase clinica specializzata nello sviluppo di terapie mirate contro il cancro, ha annunciato un nuovo programma di compensazione per i dipendenti. Il Comitato per la Compensazione dell'azienda ha approvato opzioni su azioni non qualificate per un dipendente per acquistare 45.000 azioni di azioni ordinarie nell'ambito del suo Piano di Induzione 2023. Le opzioni diventeranno valide in quattro anni, con il 25% che diventerà valido dopo il primo anno e la parte rimanente che diventerà valida mensilmente in rate di 1/48, a condizione di continuare a lavorare.

Tempest Therapeutics (TPST), una empresa biofarmacéutica en fase clínica centrada en desarrollar terapias contra el cáncer, ha anunciado una nueva concesión de compensación para empleados. El Comité de Compensación de la empresa aprobó opciones sobre acciones no calificadas para que un empleado compre 45,000 acciones comunes bajo su Plan de Inducción 2023. Las opciones se consolidarán durante cuatro años, con un 25% consolidándose después del primer año y la porción restante consolidándose mensualmente en cuotas de 1/48 a partir de entonces, sujeto a la continuación del empleo.

템페스트 테라퓨틱스 (TPST)는 항암 치료제를 개발하는 임상 단계 바이오텍 기업으로, 새로운 직원 보상 프로그램을 발표했습니다. 회사의 보상 위원회는 한 직원이 2023 유도 계획에 따라 45,000 주식의 보통주를 매입할 수 있는 비자격 주식 옵션을 승인했습니다. 이 옵션은 4년 동안 취득되며, 첫 해 후에 25%가 취득되고 나머지는 그 이후 매월 1/48씩 취득됩니다. 이는 지속적인 근무를 조건으로 합니다.

Tempest Therapeutics (TPST), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies ciblées contre le cancer, a annoncé un nouveau programme de compensation pour les employés. Le Comité de Compensation de l'entreprise a approuvé des options d'actions non qualifiées permettant à un employé d'acheter 45 000 actions ordinaires dans le cadre de son Plan d'Induction 2023. Ces options seront acquises sur quatre ans, avec 25 % acquises après la première année et le reste acquis mensuellement à raison de 1/48, sous réserve de la continuation de l'emploi.

Tempest Therapeutics (TPST), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung gezielter Krebsmedikamente konzentriert, hat eine neue Mitarbeitervergütung bekannt gegeben. Der Vergütungsausschuss des Unternehmens genehmigte nicht qualifizierte Aktienoptionen für einen Mitarbeiter, um 45.000 Stammaktien im Rahmen seines Induktionsplans 2023 zu kaufen. Die Optionen werden über vier Jahre vollständig, wobei 25% nach dem ersten Jahr und der verbleibende Teil monatlich in Raten von 1/48 erworben wird, abhängig von der Fortsetzung der Beschäftigung.

Positive
  • Stock-based compensation helps align employee interests with shareholders
  • Structured vesting schedule promotes employee retention
Negative
  • Potential shareholder dilution from 45,000 new stock options

BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 45,000 shares of its common stock under the Company’s 2023 Inducement Plan.

The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.

About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

1 If approved by the FDA


FAQ

How many shares were granted in TPST's latest stock option grant?

Tempest Therapeutics granted stock options to purchase 45,000 shares of common stock to one employee.

What is the vesting schedule for TPST's February 2025 stock options grant?

The stock options vest over 4 years, with 25% vesting after the first year and 1/48th vesting monthly thereafter, subject to continued employment.

Under which plan were TPST's new stock options granted?

The stock options were granted under Tempest Therapeutics' 2023 Inducement Plan.

How will TPST's February 2025 stock option grant affect shareholders?

The grant will result in potential dilution of existing shareholders as it adds 45,000 new shares to the potential outstanding share count upon exercise.

Tempest Therapeutics, Inc.

NASDAQ:TPST

TPST Rankings

TPST Latest News

TPST Stock Data

39.60M
43.57M
0.24%
23.02%
10.47%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE